HMGCR and malignant colon neoplasm: In patients receiving HMG-CoA reductase inhibitors (pravastatin, simvastatin), the number of newly diagnosed colon cancer cases reduced by 43% and 19% during a 5-year follow-up period (Sacks et al. 1996; Pedersen et al. 1996).